RESUMO
Purpose: Benralizumab is a monoclonal antibody that targets the α subunit of the IL-5 receptor. Clinical trials have demonstrated the efficacy of this agent with respect to lung function and symptom control in patients with refractory eosinophilic asthma. However, few studies have evaluated the efficacy of benralizumab after switching previous treatment with other monoclonal antibodies. Patients and Methods: We performed a multicenter retrospective study under conditions of daily clinical practice. The study population comprised consecutively included patients with severe refractory eosinophilic asthma whose initial treatment with omalizumab or mepolizumab was switched to benralizumab. Patients were evaluated at 4 and 12 months after starting treatment with benralizumab. We analyzed asthma control, number of severe exacerbations, corticosteroid cycles, visits to the emergency department, and hospital admissions, as well as lung function. Similarly, we evaluated the response to treatment according to previously established criteria. Results: We evaluated 40 patients who switched from omalizumab (n=16) or mepolizumab (n=24) to benralizumab. The reasons for switching were lack of response in 30 cases, adverse effects in 9, and patient request in 1. Switching was followed by a significant decrease in the number of exacerbations, visits to the emergency department, and corticosteroid cycles, as well as improved ACT both at 4 and 12 months. However, no significant improvement in lung function was observed. Asthma control (including complete response and control) was achieved in 55% of patients (n=22) at 12 months. Specifically, a complete response was achieved in 30% of patients at 12 months (66.7% switching from omalizumab and 33.3% from mepolizumab). Conclusion: Patients diagnosed with severe refractory eosinophilic asthma who experience a partial response with omalizumab or mepolizumab could benefit from switching to benralizumab. This approach can reduce the number of exacerbations, visits to the emergency department, and corticosteroid cycles and improve control of asthma.
RESUMO
No disponible
Assuntos
Humanos , Masculino , Adulto , Pneumorraque/diagnóstico por imagem , Enfisema Mediastínico/complicações , Asma/complicações , Vértebras Cervicais/diagnóstico por imagem , Vértebras Cervicais/patologiaRESUMO
El control colinérgico de la vía aérea en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) hace que los fármacos anticolinérgicos sean el tratamiento de elección de la obstrucción crónica del flujo aéreo en estos pacientes. El tiotropio, un anticolinérgico de acción prolongada y con afinidad específica por los receptores M3, permite una dosificación única que, junto con la ausencia de efectos secundarios y la carencia de taquifilaxia, favorece el cumplimiento y lo convierte en el fármaco de elección en el tratamiento de la EPOC estable. Este fármaco ha demostrado diversas acciones beneficiosas como efecto broncodilatador, con mejoría del volumen espiratorio forzado en el primer segundo y la capacidad vital forzada; reducción de la hiperinsuflación pulmonar; disminución del número, la intensidad y la gravedad de las exacerbaciones agudas de la EPOC, así como mejoría de la disnea, de la tolerancia al ejercicio y de la calidad de vida relacionada con la salud. Su asociación con agonistas β2 de larga duración y su efecto sobre la caída del flujo aéreo parecen las acciones más prometedoras (AU)
No disponible
